fda banned semaglutide ban The FDA has removed semaglutide injection products (GLP-1) from the shortage list Semaglutide FDA Approval vs Compounded
Description
When clinically appropriate, a licensed provider may prescribe a GLP-1 or GLP-1/GIP medication to help with appetite and metabolism

The concentration is sharper than the population distribution
Side Effects of Injections In addition to the typical side effects of GLP-1s, such as constipation, nausea, bloating, vomiting, and diarrhea, injections have their own potential side effects

Patients should never take both medications simultaneously, as research on concurrent use remains limited

CVOT trial will help determine if tirzepatide can demonstrate superior cardiovascular safety and potential additional cardiovascular benefits compared to the currently approved GLP-1RA dulaglutide